Posted by Michael Wonder on 24 Nov 2020
VBI Vaccines announces submission of marketing authorisation application for 3 antigen prophylactic hepatitis B vaccine to the European Medicines Agency
23 November 2020 -VBI Vaccines today announced the submission of a marketing authorisation application to the EMA for the Company’s 3 antigen prophylactic hepatitis B vaccine candidate, seeking approval for the prevention of infection caused by all known sub-types of the hepatitis B virus in adults.
This vaccine is the only 3 antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and is approved for use and commercially-available in Israel.
